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Abstract 
Torque teno virus (TTV) is a small, non‐enveloped animal virus that contains a single‐
stranded, circular DNA genome of 3.8 kb. Related to chicken anemia virus (CAV), TTV's ORF 3 
may express a 105 residue protein which is homologous to CAV VP3 (apoptin)‐‐a protein shown 
to multimerize and trigger apoptosis in cancer cells via a mechanism that involves nuclear 
translocation. Using gene synthesis, we generated the TTV ORF3 and expressed the gene fused 
to GFP. Here we demonstrate that TTV VP3 localizes to the cytoplasm of H1299 lung cancer 
cells and shows evidence of cytoplasmic aggregation. This aggregation is strikingly similar to 
CAV apoptin and may indicate a similar multimerization capacity for TTV VP3. However, an 
altered localization pattern may suggest a different mechanism of action.
 1 
 
Introduction 
 
Viruses are discovered with some regularity, but often it requires years of research to 
evince the true behavior, significance, and impact of such agents. In the unique case of torque 
teno virus (TTV), more than a decade of research has unearthed little about its role in the 
human body or its viral mechanisms.  
Discovered in the serum of a Japanese hepatitis patient in 1997, TTV was initially 
introduced as a novel hepatitis agent. [19] TTV's heightened prevalence in hepatitis patients has 
driven considerable investigation as to the virus's role in hepatitis infection as well as other 
human diseases. However, more than a decade of research has presented no evidence 
connecting TTV with any known pathology. Through epidemiological studies, it has been shown 
that TTV is present in over 90% of the adult population. [1] In addition, alternate TTV genotypes 
have been found in numerous other mammalian species, including chimpanzees, chickens, pigs, 
cows, and dogs. Despite its near‐ubiquity among humans, no evidence has been presented to 
correlate TTV infection with any kind of human disease; in addition, much about the biological 
nature of TTV is still unknown. [5,8]  
TTV is a small, nonenveloped virus with a single‐stranded, antisense DNA genome of 
length 3.8 kb.  Three polycistronic transcripts are produced from the genome, which encode 
only three putative proteins. Despite this simplicity, TTV is a virus of immense genomic 
diversity, with over 5 taxonomic groups and 40 genotypes spanning numerous species. TTV is 
currently classified into an unassigned genus Anellovirus, and although currently not part of 
taxonomic family, TTV was initially designated to the Circoviridae family, due to a number of 
distinctive structural similarities. The proteins expressed by TTV have been poorly characterized 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[8], with little known about their expression or function. This difficulty is due to a number of 
significant obstacles regarding its study: with all its genotypes combined, TTV is nearly 
ubiquitous in all infected species; its lack of known pathogenicity complicates the 
understanding of its biological function; finally, no culture system has been developed for 
growing TTV in the laboratory. All of these factors combined make investigations into the 
nature of TTV exceedingly difficult. [8] One member of Circoviridae, chicken anemia virus (CAV), 
shows an ORF orientation which closely resembles that of TTV. Significantly, CAV VP3 codes for 
the much‐studied protein apoptin, which is capable of selectively inducing apoptosis in 
transformed or tumorogenic cells. Due to their similarities in both structure and ORF 
orientation, TTV may express a protein akin to CAV apoptin, which may have similar cancer‐
killing activity. [8] 
Since 1999, a number of similarities have been drawn between TTV and CAV. Despite 
some structural differences, these viruses share a number of genomic similarities which have 
significantly advanced our understanding of TTV, allowing for parallels to be drawn between 
the proteins expressed by CAV and those of TTV. Central to this project, a team from the 
Netherlands in 2004 claimed TTV VP3 could induce apoptosis in cancer cells, much like CAV 
apoptin. [14]  
First, we will discuss the current status of TTV, its characteristics, and its history and 
then we will then detail our study of TTV VP3. Our goal was to synthesize TTV ORF3 and express 
its associated protein to study its localization and interactions in cancerous cells, and by this, lay 
the foundation for future investigations into TTV VP3 behavior and potential cancer‐killing 
ability. 
 3 
 
 
Potential pathogenicity of TTV 
In the year of TTV‘s discovery, a percentage of liver disease had no association with any 
viral agent, yet researchers speculated that other agents must exist. [26] Sparked by the 
discovery of the hepatitis C virus in 1989, scientists began investigating the presence of other 
types of viruses in hepatitis cases. They found that a substantial fraction of hepatitis C patients 
did not display any known virus indicators. In 1997, this search yielded an unknown virus from a 
group of Japanese post‐transfusion hepatitis patients. [19] The researchers isolated a DNA 
clone of the virus from a serum sample which they initially dubbed the virus “TT”, after the 
initials of the patient in which the virus was first found. This first patient had no indicators of 
known hepatitis viruses, and so TTV was initially thought to be a new agent for hepatitis, 
providing the initial drive for TTV investigations.  
In 1999, the virus had been renamed torque teno virus, from the Latin meaning “thin 
necklace” (in reference to the single‐stranded circle DNA of the virus). [26] At this point in time, 
the virus had been identified in two distinct genetic groups. This preliminary study identified 
the virus in nearly half of all unknown etiology hepatitis patients, as well as a similar number of 
patients with chronic liver disease with unknown etiology. This result led researchers to 
speculate to the potential role of TTV in various liver‐related diseases. [8]  
Until 1998, the disease had only been found in Japanese patients. In that year, serum 
samples from 126 adult patients in the UK were tested by Naoumov et al., and among these 
patients 24 were shown to be infected by TTV. In this group, 30 were healthy individuals acting 
as a control and 72 had chronic liver diseases, 33 of whom had been diagnosed with hepatitis C. 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[14] Overall, 25% of all patients with chronic liver disease showed TTV infection, and 10% of the 
control group had TTV infection. This showed not only that TTV was present in the UK as well as 
in Japan, but also that the presence of TTV was both heightened among chronic liver patients, 
but that TTV was undoubtedly prevalent in cases other than those exhibiting liver problems. 
There was some connection, however, linking the 24 patients with TTV in this study. Of these 
24 patients, 15 had a history of either drug use or intravenous transfusions. [13]  
Further, two studies provided sound evidence for the widespread presence of TTV 
among all populations. The first was a Japanese study in 1998, which found evidence for high 
prevalence of TTV in not just individuals with chronic liver disease, but within the entire 
Japanese population. [16] The second study, conducted in 1999 by Neil et al. concluded that 
TTV was present throughout the Brazilian population. Their research focused upon the sera of 
Brazilian blood donors, most of whom were negative for hepatitis and other chronic hepatic 
disease. [16]  
In 1999, Leary et al. demonstrated that TTV is also present in a number of animal 
species. [15] In this study, several species of animal were assayed via PCR in order to find the 
presence of TTV. They conducted this study because a large body of evidence at this point 
indicated that TTV was widespread, and that perhaps animals too exhibited this virus. In 
addition, the researchers were interested in determining whether TTV had any specific 
geographic correlation. In order to test the geographic variable, this study assayed the sera 
from pigs, sheep, chickens, and cows from a number of geographic locations. TTV was found to 
be present in all of the animals tested, but not in the same percent populations exhibited by 
humans. Also, the study examined the sera of six types of primates (the study indicated that the 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samples were highly limited), with TTV found in three of the six species examined. [13] Later 
studies with animals showed little effect of exposure to TTV and that animals with TTV 
exhibited a negligible amount of liver problems. Questions arose as to whether TTVs in animals 
were, in fact, specific to non‐human species, or whether these animals harbored only human 
TTV. In 2001, Okamoto et al., found that TTV in lesser primates was distinct from that of TTV in 
humans. [14] In a follow‐up study, Okamoto et al., confirmed that TTV was present in cats, 
dogs, and that TTV was highly prevalent among pigs. [22]  
In 2002, TT virus was shown to have a heightened prevalence in cancer patients. A study 
of 101 Turkish patients, 61 of whom had various types of hepatic cancer and 45 healthy control 
subjects, were assayed for TTV infections. Of those, 23 were found to exhibit TTV, and of those 
18 were from the maligned liver group. This result presented the possibility that TTV infection, 
while present broadly among human populations, is present in higher proportions among 
cancer patients. Additionally, the presence of TTV was observed to be significantly higher in 
patients with a history of transfusions. This suggested to researchers that transfusions are 
somehow linked to TTV infection. Additionally, greater risk and prevalence of TTV among 
cancer patients could be the result of cancer‐caused immunodeficiency. [8] In 2003, it was 
elucidated that TTV is present in many types of tissue, and not just a limited selection of tissues. 
[24] In 2002, a study by Tokita et al. claimed to find a correlation between TTV load and cancer. 
Their research showed that a high level of TTV in hepatitis C patients posed a significant risk for 
those patients to develop liver cancer. [23]  
At this point in time, it has been determined that TTV presence within any particular 
patient can be greatly heightened due to the immunological state of the patient. In a 2001 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study, Zhong et al. showed that using a high‐TTV concentration cutoff, over 90% of cancer 
patients showed the presence of TTV, compared to 4% in the control group. [30] This study 
showed nearly a 100‐fold increase in TTV concentration in cancer patients. This study by Zhong 
et al. suggested that this high level of TTV concentration in cancer patients may be directly 
related to the immunological state of a patient, and that TTV may not have any other significant 
linkage to cancer. [30] 
Advancements of TTV screening techniques became a crucial part in discovering more 
about the virus. It is believed that of the major reasons behind the unknown pathogenic effects 
of TTV is the highly varied nature of methodologies used to study the virus. Several efforts have 
been made to standardize the study of TTV. Numerous types of PCR have been utilized to 
screen for TTV, but only a few have been used repeatedly in TTV studies. Most research has 
shown that the most common genotype of TTV is genotype 1, which is often screened by UTR 
PCR—which detects the presence of the relatively conserved untranslated region (UTR) of TTV. 
[23]  
 
Characteristics of TTV 
Study of TTV as a pathological agent had revealed that TTV is nearly ubiquitous 
worldwide among humans, as well as in many mammalian and avian species. [1] Despite nearly 
eleven years of research into TTV‘s role as a pathological agent, no solidified connection has 
ever been made between TTV and any type of contagion. So as it stands, TTV appears to be 
completely innocuous in humans and animal species. TTV is transmitted both fecally and orally, 
and a recent study by Griffen et al. theorizes that TTV, due to its ease of detection and 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prevalence, may be an improved indicator of viral pathogens in drinking water, as opposed to 
using bacterial indicators. TTV is a small semi‐spherical viral particle, with a diameter of 
approximately 30 nm. TTV particles, when found in circulation within serum, are complexed 
with immunoglobulin G (IgG), and when found in human feces, TTV appears almost entirely as a 
free viral particle. Because IgG binds TTV, TTV can be isolated and visualized by electron 
microscopy. [8]  
 
 
Figure 1: Electron micrograph of aggregated TTV particles (30‐30 nm) found in a blood serum sample. [14] 
 
Initially, it was elucidated that TTV was approximately 3.8 kilobases in length with 
negative polarity. [8] Within a few years, it was shown that TTV was a nonenveloped virus with 
a single‐stranded, circular DNA genome. Several other families of viruses share these 
characteristics: the bacterial viruses Inoviridae and Microviridae, the plant viruses 
Geminiviridae and Nanoviridae, and the animal viruses of Circovirdae. Unlike the 
aforementioned taxonomic groups, TTV is the first human virus with these characteristics. [9] 
Owing to these similarities, TTV was arbitrarily assigned to the Circoviridae family, alongside 
viruses such as chicken anemia virus (CAV) and pocine circovirus (PCV). However, TTV has 
antisense open reading frames (ORF), while those of Circoviridae are ambisense (transcribed on 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both strands), with the exception of CAV which is antigenomic. In addition, TTV’s genome is 
significantly larger than the viruses of Circoviridae. [13] Due to these differences between TTV 
and the viruses belonging to the Circovirdae family, TTV was assigned to the “floating” genus, 
Anelloviridae (where floating is used to mean a currently unassigned or orphaned taxonomic 
designation). [10] Recently, it has been proposed that due to the enormous diversity of TTV, 
these viruses should be assigned as a new taxonomic family, Anelloviridae. Interestingly, Hino 
et al. have supported the redesignation of CAV from Circoviridae into the same taxonomic 
family as TTV (Anelloviridae, or whatever the taxonomic designation becomes), or even a family 
on its own. [9] 
In 1999, Miyata et al. published a study on the TTV strain TA278, showing a number of 
similarities between TTV and CAV. Because an understanding of the similarities between TTV 
and CAV provides evidence for our later discussion—and because many of these characteristics 
were initially studied in comparison to those of CAV—we will discuss and contrast them here in 
some depth.   
TTV exhibits broad infection diversity—TTV is present in over 20 mammalian and avian 
species. In addition, genetic analysis has revealed that TTV has an immense genomic diversity, 
or heterogeneity, with only 60% homology across all of the known TTV genotypes. [5] The 
genotypes of TTV have been represented in a number of methods across several studies, and 
the last few years have seen several reorganizations of the structure of TTV genotypic 
structuring. In general, TTV is generally organized into five or six groupings of genotypes; each 
genotype group is based upon several factors. Primarily, the groups are organized by similarity 
of order of discovery, genetic structure and relative homology. In addition, a number of 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groupings exist exclusive of the human genotypes, often depicted in their own cladogram; 
these being genotypes only found in animal species, with an entire group for primates, as well 
as one for bovine and porcine genotypes. [8] The genotypes of TTV show so much diversity that 
it is suspected that TTV may have number of distinct pathologies spread across its myriad 
genotypes. [7] Part of TTV‘s diversity, according to Manni et al. is due to a high level of genomic 
recombination, which they analyzed by studying various phylogenic groups of TTV. In contrast 
to TTV, this genomic diversity is one area where CAV notably differs from TTV. Unlike TTV, CAV 
has a fairly conserved genotype. [9] 
A TTV variant called the torque teno mini virus (TTMV) was discovered in 2000. [2] It is a 
2.9 kilobase virus, but its relative genomic framework is nearly identical to the genomic 
structure of TTV. TTMV is also exceedingly diverse, and has similarly numerous genotypes to 
those of TTV. Researchers found that most humans are infected with both TTV and TTMV 
simultaneously. Scientists believe that a further comparison of TTMV may aid in the 
understanding of TTV‘s physiological role, and potential pathological function. [2, 29]  
Despite its high level of genotypic variance, TTV has a highly conserved genetic 
framework. All of its genotypes share a similar length, with most approximately 3.8 kb in length. 
The variance of TTV, when seen across a large selection of its genotypes is between 3.6 and 3.8 
kilobases. [3, 12]  
  It has been observed that over one‐third of the TTV genome is comprised of UTR. [9] 
This UTR is one unifying characteristic of the various TTV genotypes, with a high degree of 
sequence conservation among the genotypes, including those genotypes that are considered to 
have highly divergent sequences. One common feature of the various TTV UTRs is the presence 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of an inclusive GC‐rich 113 nt region. [27] Within this region is a 36 nt stretch which forms a 
stem‐loop structure and serves as the origin of DNA replication for TTV. Like TTV, CAV has a 36 
nt stem‐loop forming region at the origin of replication and CAV shares over 80% homology 
with TTV for this particular region; however, this is the only region of significant sequence 
homology between CAV and TTV, for the rest of their DNA there is little similarity in their exact 
nucleotide sequence. [27] 
 
 
Figure 2: TTV transcribes three messenger RNAs of lengths 3.0 kb, 1.2 kb, and 1.0 kb. For each transcript, ORF 3 
codes for TTV‐VP3, our protein of interest. 
 
In addition, all genotypes thus far studied by researchers have a very similar set of ORFs 
and spliced mRNAs. TTV possesses three conserved spliced mRNAs, with lengths of 3.0, 1.2, and 
1.0 kb. In TTV, three ORFs are known to exist, here denoted as ORF1, ORF2, and ORF3. [3,7] 
ORF1 is present in every genotype of TTV, but is only partially conserved across many of the 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more distally related genotypes of TTV. ORF2 consistently appears with similar variability. ORF3 
is present in all mRNA transcripts, and ORF3 overlaps with ORF2, but in a different reading 
frame. [12] In TA278, all transcribed mRNAs use the same TATA box and poly‐A signal, found on 
the antisense strand at bases 86‐90 and 3073‐3079, respectively. Also in TA278, transcriptional 
regulation is controlled by critical regulatory elements at ‐76 and ‐154 nt which govern the TTV 
promoter. [9] In addition, each mRNA transcribed by TTV is polycistronic, with one ORF in each 
of its reading frames. [8] CAV also transcribes multiple mRNAs, although most CAV studies have 
focused upon the transcription of its large, unspliced mRNA of 2.0 kb, and have given little 
focus to its spliced mRNAs and their putative proteins. Further, the genomic distribution of the 
putative ORFs of both TTV and CAV are quite similar, providing evidence that the biological 
functions of their respective viral proteins may share a common function at some level. [8,9, 
27] 
Due to a number of limitations, studies into the proteins of TTV have been mostly 
unsuccessful. There is currently no culture system for TTV, making a study of the expression and 
function of its proteins difficult. In addition, many of the TTV genotypes are present 
simultaneously, making their individual separation and study complicated. [8]  
The similarities in both ORF distribution and genomic structure of TTV and CAV have led 
researchers to hypothesize, that like CAV, TTV expresses three main viral proteins. [13] 
However, TTV has been reported in some cases to produce greater than three proteins. One 
study, using TTV genotype 6, purports that TTV expresses up to seven distinct proteins; 
however, the remaining four proteins are all coded by the alternately spliced mRNAs of lengths 
1.0 and 1.2 kb, and because they are expressed in considerably lower populations than those 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proteins coded by ORF1, ORF2 and ORF3, their role in TTV has yet to be investigated. [25] The 
functions of CAV’s three proteins, VP1, VP2, and VP3, have been established to some degree. 
VP2 and VP3 are believed to be early proteins, as they are often expressed approximately 
twelve hours after infection. VP1 is likely a late protein, as it is often seen expressed at twenty‐
four hours or later. VP1 is a protein which has been shown to exist exclusively in the capsid of 
the virus, and it is believed that this protein forms the capsid. [14, 20] Further, in 2001, 
Yamaguchi et al. showed that the mutation of a particular glutamine to a histidine results in a 
loss of pathogenicity for CAV. VP2 is less well characterized, but it is has been speculated, by 
Noteborn et al. to serve a role as a scaffold protein in the assembly of the virus. Evidence 
towards this proposed role for VP2 as a scaffold protein was provided by Noteborn and 
colleagues, who showed that expressing only VP1 or VP2 does not allow for the generation of 
CAV‐specific antibodies (which bind the capsid). [20] This suggests that both VP1 and VP2 must 
be expressed to generate the fully functional capsid, and so VP2 must play some role in the 
assembly of VP1 into a capsid structure. In addition, VP2 in both CAV and the ORF2 of TTV have 
been shown to have phosphatase activity. VP3 of CAV, known as apoptin, is a non‐structural 
protein of 121 residues has been shown to induce apoptosis, within various types of cells after 
infection. Further, apoptin has been shown to cause apoptosis specifically in transformed or 
tumorigenic cell lines, but not in normal cells. Additionally, apoptin is able to induce apoptosis 
independent of p53, a key protein in tumor suppression and cellular growth, which is often 
overridden by transformed growth. [9] Hino et al., in research submitted for publication, have 
reported that apoptin is necessary element in both the processes of CAV virion formation and 
DNA replication.  For both CAV and TTV, their spliced mRNAs (for TTV, the 1.0 and 1.2 kb 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mRNAs) can also generate proteins, however, if these other proteins play a role in the biological 
function of either virus it has yet to be demonstrated. [9, 27] 
For TTV, ORF1 codes for a protein of 770 amino acids. ORF1 contains several conserved 
replicase protein motifs, as well as a highly basic region near its N‐terminus. These two 
properties have lead researchers to believe that this ORF codes the major structural protein of 
TTV, as the two aforementioned properties are both qualities present in circoviral capsid 
proteins. Less is known about the protein coded by ORF2, although it occupies a similar 
orientation to that of CAV ORF2, and so it may too act in some sort of structural assembly 
function. [8] The protein for ORF3, TTV‐VP3, is coded for by all three mRNAs. Like apoptin, TTV‐
VP3 has been reported to be a non‐structural protein of 105 residues. To a greater degree than 
the other two main proteins coded by TTV, TTV‐VP3 shows a number of structural qualities to 
apoptin. Their primary sequences bear little resemblance, but the makeup and distribution of 
amino acids in TTV‐VP3 is perhaps the strongest indicator of their similar biological function. 
First, TTV‐VP3 and apoptin have a high level of proline residues—10.5% for TTV‐VP3 and 11.5% 
for apoptin. Further, these are in a highly dispersed distribution, suggesting that these residues 
serve a structural function in the respective viral proteins. Another shared quality is their high 
concentration of threonines—TTV‐VP3 has 12.4%, while apoptin has 11.5%—suggesting that 
threonines play an important structural role for both. Finally, both TTV‐VP3 and apoptin contain 
a section of hydrophobic amino acids close to their N‐terminus which forms the site of apoptin 
multimerization and export. These three similarities are significant enough support the idea 
that TTV‐VP3 may harbor some similar activity to apoptin. [9, 27] 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Table 1: This table provides a simplified overview of some of the major similarities and differences between the 
viruses TTV and CAV. 
 
Recently, a study published by Noteborn et al. reported that TTV ORF3 has a similar 
function to that of the VP3 of CAV, apoptin. [14] In an undisclosed method, these researchers 
expressed the protein of ORF3 from TA278, genotype 1 of TTV, and transfected the protein in 
hepatocellular carcinoma cells (HCC). They also claimed that TTV VP3 was able to induce 
apoptosis in a similar manner to apoptin in CAV, although on a more limited scale. In addition, 
they made a thorough comparison of the overall genomic framework of TTV and CAV which 
they used as their foundation for their work with the TTV protein. They named the protein “TTV 
apoptosis‐inducing protein”, TAIP, and in the conclusion of the report, Noteborn et al. proposes 
TTV VP3 as a potential cancer therapeutic. [14] In subsequent years, no further reports have 
made further headway into the study of TTV VP3, and in the past several years a number of 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reports have noted that the research into TTV VP3 by Noteborn et al. lacked clarity. Through 
correspondence with Mathieu Noteborn and his laboratory in Leiden, Netherlands, it has been 
established that all known samples of the ORF gene and TTV VP3 in their possession have been 
lost due to a laboratory move. Despite these setbacks, we believe TTV VP3 remains one of the 
most intriguing aspects of TTV and merits an exhaustive study.  
In the following sections we will discuss our work to synthesize TTV ORF3 and to study 
the expression and behavior of TTV VP3. By synthesizing the gene for ORF3, we will be able to 
study the expression of TTVVP3 extensively. Through this work, it is our hope to build a 
foundation for—and perhaps reignite interest in—this poorly characterized protein, which may 
indeed share some activity with apoptin. 
 
Materials and Methods  
 
Phylogenic analysis  
     Based on the GenBank accession number (AB008394) and ORF3 sequence published by 
Noteborn et al., we positively identified the TTV strain as TA278—the prototypic TTV strain. 
Sequence analysis and homology comparisons were performed between TA278 and a number 
of other TTV strains based upon the phylogenic groupings from Jelcic et al., and Hino and 
Miyata. [8, 6] Special focus was given to determining the homology of TA278's ORF3 with those 
genotypes of the same phylogenic group. In addition, cross comparisons were made between 
TA278's ORF3 sequence and those of numerous genotypes, both human and animal, more 
distantly related (as evidenced by their phylogenic groupings and overall sequence heterology). 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TTV ORF3 construct design  
 
TTV VP3 Sequence, 40bp oglionucleotides  Contains 
1. gcGAATTCaatgatcaacactaccttaactggcaatggt (39 nt)  1.EcoRI restriction site, 2.start codon 
2. actcaagtatacttagctcccacgctgctatgtgcgggtg 
 
 
3. tcccgacgctgtcgctcattttaatcatcttgcttctgtg 
 
 
4. cttcgtgccccgcaaaacccaccccctcccggtccccagc 
 
 
5. gaaacctgcccctccgacggctgccggctctcccggctgc 
 
 
6. gccagaggcgcccggagatagagcaccatggcctatggct 
 
 
7. ggtggcgccgaaggagaagacggtggcgcaggtggagacg 
 
 
8. cagaccatggaggcgccgctggaggacc (28 nt)   
 
 
TTV VP3 Reverse Compliment, 40bp oglionucleotides  Contains 
1. gcGGATCCgtctagcaggtctgcgtcttcgggtcctccag  BamHI restriction site 
 
2. cggcgcctccatggtctgcgtctccacctgcgccaccgtc 
 
 
3. ttctccttcggcgccaccagccataggccatggtgctcta 
 
 
4. tctccgggcgcctctggcgcagccgggagagccggcagcc 
 
 
5. gtcggaggggcaggtttcgctggggaccgggagggggtgg 
 
 
6. gttttgcggggcacgaagcacagaagcaagatgattaaaa 
 
 
7. tgagcgacagcgtcgggacacccgcacatagcagcgtggg 
 
 
8. agctaagtatacttgagtaccattgcca  (28 nt) 
 
 
Table 2: Oligonucleotides used for PCR‐directed gene synthesis, forward and reverse complement. 
 
Initial PCR assembly was performed under the influence of several variables, allowing 
for a broad range of observable product efficiency. The 16 construct oligonucleotides were 
initially mixed into a single‐tube mixture, each segment added at a volume of 1ul. This mixture 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(containing the full‐length gene in 16 oligonucleotide segments) was split by volume, with half 
of the sample being set aside at room temperature. The remaining mixture was heated to 95 C 
and then allowed to cool slowly for an extended period of time at room temperature. This was 
done in order to facilitate the thermodynamic formation of pre‐annealed complexes of 
oligonucleotides. The pre‐annealed mixture along with the remaining mixture were each 
distributed among numerous reactions, each reaction at a total volume of 20ul. These reactions 
were conducted in a PCR mix comprised of 1 µl oligonucleotide mixture, 1 µl of Taq polymerase 
(Promega), 0.02 of Pfu polymerase (Stratagene), 5 µl of Taq buffer, 1 µl of 0.2 mM dNTPs, with 
remainder volume of distilled water to a volume of 20 µl. Pfu polymerase was utilized in 
conjunction with Taq polymerase for its high degree of proofreading ability and processivity.  
The base PCR program was varied in regards to stringency and number of total program 
cycles. Stringency variation consisted of altering the annealing temperature for the second 
stage of PCR. Half of all reactions were run at 60 C, while the other half were run at low 
stringency 52 C; for our purposes, these will be considered high and low stringency, 
respectively. Varying the annealing base temperature, we postulated, may allow for 
preferential annealing of longer assembled DNA products, perhaps increasing the overall 
efficiency of generation for full‐length genes. Based on the techniques provided by Stemmer et 
al., we considered 55 cycles to be the maxima for cycle number. In addition, we ran PCR 
reactions at two lower cycle numbers, 40 and 25 cycles. All of the reactions, in conjunction with 
the previously mentioned variable divisions, were again subdivided into three batches (one 
third of all samples in each division), based on cycle number. In this manner, the three variables 
(pre‐annealing, stringency, and cycle number) resulted in 12 unique reactions. Two samples of 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each reaction type, for a total of 24 reactions, were run through the PCR program with the 
appropriate cycle number. The PCR program consisted of repeating cycles of 94 C for 30 
seconds, 52 or 60 C for 30 seconds, and 72 C for 30 seconds. All 24 samples were visualized by 
electrophoresis on a 0.9% agarose gel. 
All of the pre‐annealed 40 and 55 cycle samples displayed optimal bands, in regards to 
both size and concentration, and so these 8 PCR products were carried forward and amplified 
with primers consisting of the N‐terminus forward primer and the C‐terminus reverse primer 
and using Pfu polymerase for proofreading. This amplification was done in order to ensure a 
contiguous full‐length product. For this round of amplification, the PCR program consisted of 40 
cycles of 94 C for 30 seconds, 52 C for 30 seconds, and 72 C for 30 seconds. With its completion, 
the various PCR samples were visualized by electrophoresis on a 0.9% agarose gel. Those 
samples which displayed the optimized band length (approximately 330‐340 bp), band range 
and product concentration were selected. These products were excised from the agarose gel 
and the DNA product purified via a GeneClean Kit (MP Biomedicals). Duplicate samples of the 
same variety were combined to increase overall product volume.  
Due to the polyadenylation generated by Taq polymerase, a final round of PCR 
reamplification was conducted in the absence of Pfu polymerase. Before reamplification, the 
PCR products were visualized on a 0.9% agarose gel at three dilutions with distilled water to 
final concentrations of 1/100, 1/1000 and 1/10000 of the original sample concentration. The 
most refined bands were those of the 1/1000 dilution. These agarose bands were excised and 
purified as mentioned above. The purified bands were reamplified with Taq polymerase using 
recipe described above, with the PCR program of 40 cycles of 94 C for 30 seconds, 52 C for 30 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seconds, and 72 C for 30 seconds. Four samples were selected for continuation: 40‐cycle high 
stringency, 40‐cycle low‐stringency, 55‐cycle high‐stringency, and 55‐cycle low‐stringency. In 
subsequent discussion, these samples will be designated with the monikers 40H, 40L, 55H and 
55L.  
 
Cloning, transformation and sequencing  
The synthesized genes, 40H, 40L, 55H and 55L, were cloned into a plasmid expression 
vector pGEM‐T under the control of the bacterial T7 promoter (SP6 promoter in the antisense 
direction). The vector contains a lacZ start codon and lac operatorto allow for blue‐white 
screening, and a constitutively‐expressed amp gene for conferring ampicillan resistance. The 
DNA samples were ligated into this plasmid vector, creating the constructs pTTV‐VP3 40H, 40L, 
55H and 55L. The constructs were transformed into competent DH5α E. coli cloning strain cells. 
For instance, DH5α E. coli utilizes a mutated RecA allele to prevent integration of plasmids by 
homologous recombination. The pTTV‐VP3 constructs 40H, 40L and 55H were positively 
selected via blue‐white screening from ampicillin plates coated with 0.1 mM  IPTG and 40 µg/ml 
X‐gal. These positive colonies were inoculated and grown overnight in 2 ml LB media with 2 µl 
100 mg/ml ampicillin  and the plasmid constructs were harvested from 1.5 ml of culture using 
small‐scale DNA purification technique [details]. Construct DNA was isolated and resuspended 
in 1 M TE buffer (10 mM Tris/1mM EDTA) to a final volume of 50 µl. The construct DNA was 
digested by enzyme restriction of EcoRI and BamHI to verify proper transformation and ligation. 
The restrictions were conducted at 37 C for 1 hour in the presence of 1 µl RNAse A and then 
visualized by electrophoresis on a 0.9% agarose gel. With confirmation of the correct insert size, 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the remainder of the DH5α E. coli cultures (0.5 ml) were used to inoculate three large‐scale 
cultures of 100 ml LB media with 100 µl 100 mg/ml ampicillan which were incubated overnight 
at 37 C. The cultured cells were harvested, and the cells were lysed and the plasmid vector was 
purified with a MidiPrep kit (Promega). The construct DNA was resuspended in 300 µl distilled 
water. Again, the purified DNA was digested by enzyme restriction of EcoRI and BamHI to verify 
the presence of proper‐length insert. Using UV spectroscopy, the concentrations of the three 
construct samples were determined and used to create final dilutions for sequencing 
(Macrogen USA Inc.).   
 
Cloning into GFP and 3xFlag vectors  
The lone successful sequence, pTTV‐VP3 40L, was restricted with EcoRI and BamHI and 
the insert was purified using a GeneClean Kit (MP Biomedicals). The 40L gene was then cloned 
into both a pEGFP‐c1 vector and a 3xFlag vector (Sigma‐Aldrich). The pEGFP‐c1 allows for the 
expression of target proteins with a N‐terminal GFP tag. This would create a functional TTV VP3 
fusion with a GFP vector, allowing for visualization of protein localization in vivo by fluorescence 
microscopy. This vector is under the control of the cytomegalovirus (CMV) promoter and 
contains the gene for kanamycin resistance. The 3xFlag vector is under the control of the 
cytomegalovirus (CMV) promoter region which drives constitutive control and it contains the 
gene for ampicillan resistance controlled by a seprate promoter [6]. The 3xFlag vector was used 
to express TTV ORF3 in conjunction with three small protein tags, allowing the protein to be 
cloned into human cells for killing assays with an unobtrusive tagging system. In addition, 
3xFlag is an excellent epitope, being easily bound by a corresponding 3xFlag antibody. For the 
 21 
 
pEGFP‐cl vector, the insert was ligated at a ratio of 3‐to‐1 (6 µl:2 µl), insert‐to‐vector ratio. This 
construct, pVP3‐GFP, was transformed in DH5α E. coli and plated on kanamycin plates. For 
3xFlag, ligation was conducted at a ratio of 4‐to‐1, insert‐to‐vector, and the resultant construct 
pVP3‐Flag vector was transformed into DH5α E. coli and plated on ampicillin plates. Positive 
colonies were selected and grown overnight in 2 ml LB media with 2 µl 100 mg/ml kanamycin or 
ampicillin and the DNA was harvested from 1.5 ml of culture using small‐scale DNA purification 
technique as detailed above. Both vectors were isolated and resuspended in 50 µl 1 M TE 
buffer. The construct DNA was digested by EcoRI and BamHI restriction to verify transformation 
and ligation. The restrictions were conducted at 37 C for 2 hours in the presence of 1 µl RNAse 
A and then visualized by electrophoresis on a 0.9% agarose gel. With a positive restriction, the 
remainder of the vector‐transformed DH5α E. coli cultures were used to inoculate large‐scale 
cultures with different pVP3‐GFP and pVP3‐Flag samples in 100 ml LB media with 100 ul 
kanamycin or ampicillin, respectively. After incubating for twenty‐four hours, cultured cells 
were harvested and lysed. The plasmid vector was purified by a MidiPrep kit (Promega). The 
isolated construct DNA preparation was resuspended in 300 µl distilled water. To confirm the 
construct's successful isolation, the DNA was digested by restriction with EcoRI and BamHI. 
Using UV spectroscopy, the concentrations of the construct samples were determined and used 
to create final dilutions of for sequencing (Macrogen USA Inc.). 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Tissue culture and transfection  
Tissue culture experimentation was carried out in a tumorogenic human cell line H1299, 
or NCI‐H1299. H1299 is an adherent, cancerous lung cell line derived from the lymph node. [18] 
After removal from cryostasis, the H1299 cells were maintained in DMEM and 10% PBS.   
Transfections were performed in six‐well tissue culture plates as described by the 
Effectene protocol. For each well, a circular coverslip was first placed in the basin and then to 
each well 2 ml of cell‐containing prediluted media was added. This prediluted media was 
seeded with the passaged cells to reach 70% confluence for the next day. After growing for 
twenty‐four hours, or achieving the proper confluence, the six‐well plate was transfected. In 
this way, the coverslip‐bound cells can be transfected and mounted for visualization. Multiple 
rounds of transfections were done in order study localizations a multiple time points according 
to the Quiagen Effectene protocol. To each plate, two identical samples and one control were 
added across the six wells. The control was transfected with a GFP‐expressing construct to 
achieve a uniform GFP localization pattern.  
      For the pVP3‐GFP construct, the transfections were carried out in H1299 cells in two 
rounds. These were fixed with 4% paraformaldehyde in 1M non‐sterile PBS approximately one 
day following transfection to generate a twenty‐four hour sample and approximately two days 
following transfection to generate the forty‐eight hour sample. Once fixed, the coverslips were 
mounted on slides with 35 µl mounting media consisting of 50% glycerol, 100 mM Tris (pH 7.5), 
2% DABCO, and DAPI (nuclear stain). 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Apoptosis detection via crystal violet staining 
  Using the pVP3‐Flag construct described previously, H1299 cells were passaged and 
transfected using the standard Effectene protocol in six‐well tissue culture dishes. Two samples 
transfected with pVP3‐Flag construct occupied two wells, while a third, functioning as control, 
consisted of non‐transfected H1299 cells. Cells were observed each day following transfection 
by simple microscopy, noting changes in confluency between sample and control wells. When 
obvious confluency differences were noted, the plates were fixed (as previously described). 
Immediately after fixing, the wells were immersed in PBS and a single drop of crystal violet 
(methyl violet 10B) dye was applied to each of the three sample wells. Tissue culture tray was 
lightly swirled and allowed to incubate at room temperature for three minutes. The PBS/crystal 
violet suspension was aspirated from the cells and cells were promptly washed with PBS (to 
remove residual crystal violet), agitating for one minute, before this too was aspirated off. Cells 
were allowed to dry at room temperature.  
 
Results  
 
Phylogenic Analysis of ORF 3 
      Genotypic analysis of TTV provided us with several interesting observations. At this 
time, multiple phylogenic trees exist for TTV, but many of these fall into several distinct 
arrangements. Some are based on ORF 1 homology, drawing the TTV genotypes into clustered 
groupings; others provide a breakdown based on full genome analysis. In some cases, the 
human genotypes and lesser mammalian genotypes are separated and viewed independently. 
Due to the immense diversity of TTV—40% sequence heterology, with over 20 confirmed 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human genotypes, as well as many others from other species, including numerous swine, 
primate and bovine strains—these various published tree groupings and cladograms show an 
erratic level of relative diversity in their structure and presentation, making a conclusive study 
of TTV's genotypic relationships a near impossibility. Hino and Miyata present what is perhaps 
the most lucid phylogenic representation to date. [6] Their analysis provides a bifurcated 
cladogram, with one part providing full‐sequence‐based analysis, and the other providing a 
phylogenic representation based on the sequence similarity of the non‐translated regions of 
TTV. This second cladogram, in addition to the most studied genomic groups, also incorporates 
many new TTV strains, including a battery of novel bovine TTV strains. We selected this 
representation for its up‐to‐date and clear presentation of TTV genotypes, as well as its 
authors' encompassing understanding of TTV and its current related research. Based on Hino 
and Miyata's phylogenic representation, the prototypic TTV genotype TA278 resides in group 1, 
also comprised of JA1, T3PB, TKM1, THEM1, TFC3155. These six members of group 1 are all 
human strains, and are the most prominent of human TTV varieties. In addition, these 
genotypes are given numbered prefixes in order to indicate their order of discovery—1‐TA278 
being the first TTV genotype to be discovered. A genome‐wide comparison of sequence 
homology between these six genotypes from group 1 showed considerable similarity. Further, 
an analysis of group 1's ORF 3 showed a high degree of sequence homology, with only a few 
residues changing across the 6 genotypes. Two genotypes, TRM1 and JA9, showed almost 
complete ORF 3 homology with TA278, differing by only one and two nucleotides, respectively. 
This analysis provided sufficient evidence that the ORF 3 sequence of TA278 is quite conserved 
across the entirety of group 1, as defined by Hino and Miyata. Our further analysis, expanding 
 25 
 
the comparison of TA278's ORF 3 across the other main genotypic groups showed some 
retention of homology, with most genotypes retaining more of the TA278 sequence, on 
average, in comparison to their overall sequence. Although there was still a great deal of 
variance across genotypes, especially in full‐sequence comparisons, a logical consequence of 
the highly diverse nature of TTV. Importantly, this analysis of was conducted to verify the 
presence of ORF 3 and to objectively examine ORF 3 sequence diversity. 
 
PCR‐directed gene synthesis  
      Using PCR‐directed gene synthesis, we were able to effectively use a number of variable 
conditions, such as cycle number and degree of stringency, to synthesize the full length TTV 
ORF 3. When we observed the PCR products by gel electrophoresis, we noticed the bands to be 
approximately 330 nt in length, which was appropriate for the expected product. Next, we were 
selected those products which we observed to have the greatest potential fitness—products 
that displayed the most concentrated bands that at the same time were  most constrained to 
the acceptable range for product length. The bands which we selected were 40L, 40H, 55L and 
55H, and these we carried forward to further amplification. The degree of stringency seemed to 
have some level of effectiveness refining the PCR products, as the high‐stringency bands 
displayed a more well‐defined band range, indicating that the products were all at nearly 
identical lengths; however, this was not so significantly pronounced so as to not pursue those 
products generated by low‐stringency synthesis. Cycle number seemed to be a more critical 
factor—heavily influencing both product band range and concentration. Some bands not 
selected for further amplification showed more dispersed products, including several whose 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product bands were visualized as a long swath of product, likely indicating partially‐formed or 
aberrant products. Several others PCR products, were not selected because they displayed faint 
or overly bright bands, indicating overly‐low or too‐great product concentrations, respectively. 
In addition, little difference was displayed between pre‐annealed bands and those that were 
not; however, all of the pre‐annealed bands were selected over the others as we perceived 
their bands to be slightly more refined in contrast to those reactions which were not pre‐
annealed. Despite this, it is difficult to say the overall difference of effectiveness engendered by 
the use of pre‐annealing the PCR reactions.  
      The gel electrophoresis showed all of the product bands to be of the appropriate length 
and of a well‐defined size, indicating their successful reamplification. In order to reduce the 
chance of mutagenesis with this lengthy PCR, it was important in this process to conduct the 
initial full‐length assembly in the presence of a DNA polymerase with a high degree of 
proofreading and processivity—in this case Pfu polymerase in conjunction with Taq polymerase 
served this purpose.  
 
Engineering TTV VP3 expression vectors  
       The samples were successfully transformed into competent E. coli cloning strain DH5α 
and a large‐scale quantity of the plasmid construct pTTV‐VP3 was harvested. Analysis by double 
restriction enzyme digests, EcoRI and BamHI, confirmed the presence of the appropriate length 
fragment at approximately 310‐340 nt in length in the various samples. Despite multiple 
potentially viable samples, several 40L transformants were the only constructs successfully 
carried through to the final stages for sequencing. Of the three constructs analyzed for 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sequencing, the construct pTTV‐VP3 40L3 was the lone successful sequence. For this construct, 
all bases from the original PCR‐directed gene synthesis were successfully retained, with no 
presence of mutagenesis, damage or frameshift present in the final sample.  
       The pTTV‐VP3 construct was digested and the gene of interest was successfully purified. 
The synthesized VP3 gene was cloned into both GFP and 3xFlag vectors. After transforming the 
constructs in DH5α cell, positive colonies for pVP3‐GFP and pVP3‐Flag were selected from 
Kanamycin and Ampicillan‐enriched plates, respectively. These two types of constructs were 
grown in large‐scale culture and the plasmids were harvested and purified for sequencing. The 
sequencing analysis confirmed that both constructs were positive for the TTV VP3 gene and 
that the vectors contained the intact sequence. The two vector constructs were assessed for 
insert and linearized vector length by restriction enzyme digestion. Visualization by 
electrophoresis confirmed the presence of the correct length VP3 DNA insert in both plasmid 
systems. The linearized plasmids appeared at their correct lengths, approximately 4 kb for the 
linearized GFP vector and 6 kb for the linearized 3xFlag vector.     
 
TTV VP3 expression analysis 
       Effectene‐induced transfection was successfully conducted on H1299 adherent lung 
carcinoma cells using the pVP3‐GFP construct. H1299 cells are immortalized, and as such, can 
grow—if unhindered—indefinitely. Importantly, H1299 cells have a homozygous partial 
deletion of the p53 gene and as a result, are unable to express the p53 protein, a tumor 
suppressor. [18] The H1299 cells were transfected with the pVP3‐GFP construct in two separate 
rounds—one fixed at a twenty‐four hour time point, and another fixed at forty‐eight hours. This 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was done in order to observe the localization tendencies of TTV VP3 over time, perhaps 
allowing for the visualization of a changing localization pattern, or even the occurrence of VP3‐
induced apoptosis.       
       The GFP‐tagged VP3 distributions at twenty‐four hours (see A‐C, figure 5), although not 
particularly skewed towards any localization trend, appeared in clear contrast when viewed 
alongside those H1299 cells observed from the forty‐eight hour transfections. At 24 hours, 
there were at least three comingled states of relatively equal distribution present among the 
transfected cells. Of all the observed patterns, perhaps the most interesting localization pattern 
consisted of strong, punctate GFP signals situated in the cytoplasm of the cell, as displayed in A 
and B in figure 5. These appeared as both singleton entities, as well as clustered groupings. In 
most of these cases, the GFP signal appeared as a uniformly bright, clean‐edged foci, with little 
occurrence of any distribution gradient along the edges. This may suggest a trend towards 
cytoplasmic, proteinaceous self‐aggregation at this temporal stage. Among the transfected 
cells, GFP‐tagged VP3 localization distributions could be classified into four distinct 
populations: cells with relatively uniform GFP‐tagged protein distribution, both cytoplasmic and 
potentially nuclear, with fusion protein loci; Cells with fairly even cytoplasmic distributions, 
with punctate GFP signals; cells with purely cytoplasmic distributions but only in explicit nodes 
and clusters without any diffuse distribution; cells with predominantly nuclear distributions 
with the presence of bright GFP‐tagged VP3 loci. The most common characteristic was the 
presence of the aforementioned GFP‐tagged protein nodes. In addition, when cytoplasmic, the 
punctate signals were sometimes oriented in close relation to the nuclear membrane. In most 
of these instances, the tagged proteins were clustered in tight groups near the nuclear 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membrane (see A, figure 5). Some nuclei, especially those with lobed or curved oblong shapes, 
displayed these tagged proteins in the deepest point in their curve or their most prominent 
cleft. Those cells with both nuclear and cytoplasmic distributions showed distinctly weaker GFP 
signals in their nuclei, perhaps indicating that the nuclear concentration of tagged protein was 
either lessened, or that the strength of the cytoplasmic signal was such that it was able to 
visibly permeate through the nucleus (in such a case, the nucleus may indeed be relatively free 
of the tagged protein). One other characteristic of the twenty‐four hour pVP3‐GFP transfected 
cells was a thread‐like diffusion pattern which the tagged protein displayed at the cellular 
periphery (see A, figure 5).  
       At forty‐eight hours, pVP3‐GFP transfected cells showed a markedly different 
distribution—nearly all of the cells displayed a primarily cytoplasmic distribution (D and E, 
figure 5). These transfections all had clear nuclei (free of GFP‐tagged protein), with all nuclear 
GFP signaling the obvious consequence of strong GFP‐tagged protein concentration around the 
nuclear membrane exterior. The general cytoplasmic pattern was that the tagged protein was 
distributed throughout the cytoplasm, and with less evident protein foci, although these were 
still present. At this later stage, the punctate, GFP‐tagged proteins occupied relatively 
diminutive loci within the cell. These aggregations were often widespread and diffuse in the 
cytoplasm, appearing as a multitude of fine, bright points in a wash of green coloration. Similar 
to the twenty‐four hour transfections, a number of cells in this second round showed punctate 
protein aggregations proximal to the exterior of the nuclear envelope. These foci were often 
larger than the median‐sized protein aggregations—either the result of the amplified brightness 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of densification of small protein aggregations, or perhaps these punctate GFP signals indicate 
the presence of larger tagged‐protein aggregates.    
 
Apoptosis detection via crystal violet staining 
  After transfection, H1299 cells were observed once per day over a five‐day period. On 
the fourth and fifth days, sizable differences in confluency were observed. Cells were fixed with 
4% paraformaldehyde on the fifth day post‐transfection. Staining with crystal violet dye 
provides a strongly‐colored visual indicator as to the degree of cell confluency, allowing for 
differences to be measured by simple unaided observation. For our samples, a clear difference 
was observed between the control and those cells transfected with pVP3‐Flag, Figure 6. For 
those cells transfected with the pVP3‐Flag construct, there is a sharp contrast in cell density in 
comparison to the control cells, indicating significant cell death among the transfected cell 
populations. 
 
Discussion  
Benefits and applications of PCR‐directed gene synthesis 
      This project was extensively benefited by the use of PCR‐directed gene synthesis. This 
fairly novel technique proved to have a number of intrinsic benefits on the overall flexibility and 
efficiency of creating, verifying, and utilizing a synthesized gene. By working with a number of 
overlapping sense and antisense DNA segments, it was possible to assemble the full‐length 
TA278 VP3 in a secure and cost‐efficient method, in a variation of gene synthesis which 
Stremmer et al. refer to as "gene shuffling". [28] Each segment was purchased as a short, 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single‐stranded 40 nt oligonucleotide—significantly more cost‐effective than purchasing a full‐
length gene. Each fragment was also more stable than a larger DNA molecule, and allowed for 
accurate temperature stability information about each particular segment. Further, any small 
mutation or error could be pin‐pointed and dealt with on the scale of a small, facile 
oligonucleotide and not on the scale of a full length gene. Also, using numerous segments 
allowed for versatile amplification, where each oligonucleotide can act as an individual primer; 
future experimentation can also be benefited by the replacement of these short segments with 
mutated fragments to readily conduct mutagenesis. Based on our success, PCR‐directed gene 
synthesis, if implemented properly, could be used on significantly larger stretches of DNA. By 
ensuring an adequate number of cycles it may be possible to construct genes of thousands of 
bases in length with a high level of efficiency.  
Finally, this type of segmented assembly can also be applied to the creation of future 
alternate constructs of TA278's ORF3 in order to study the individual functions of the sequence 
on a section‐by‐section basis. By simply designing and purchasing more oligonucleotides, 
engineered with appropriate restriction sites their ends, it becomes possible to assemble new 
constructs. For instance, one may wish to determine the location of the nuclear export 
sequence (NES) of TTV VP3, and by designing various sectional constructs it will be possible to 
knock‐out nuclear export of the protein, allowing for a greater knowledge of TTV VP3's 
sectional properties.  
In this way, PCR‐directed gene synthesis provides a great advantage this type of 
experimentation, allowing for assembly of genes in modular, easy to manipulate sections. For 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this particular project, the groundwork laid out by the use of this "gene shuffling" technique will 
likely prove highly beneficial to future iterations of TTV VP3 studies. 
 
The enigma of TTV VP3 
  Despite the abundance of information provided by the florescence microscopy images 
of H1299 transfected with pVP3‐GFP, the overall behavior of the protein and its potential in 
vivo role remain largely a mystery. The fusion TTV VP3‐GFP fusion protein, as evidenced by its 
twenty‐four and forty‐eight hour distributions, has a great deal of time‐dependent 
localization. In the case of the twenty‐four hour samples, the fusion protein displayed a wide 
range of distributions, both cytoplasmic and nuclear. For those cells fixed at forty‐eight hours, 
the fusion protein had clearly shifted towards to a primarily cytoplasm‐exclusive 
distribution. Understanding this general localization shift may aid in developing an 
understanding of the dynamic temporal behavior of TTV VP3. 
For those cells fixed at twenty‐four hours, there seems to be little correlation between 
the fusion protein’s presence and any particular region within the cytosolic environ. Two 
cytoplasmic regions showed noteworthy distributions: the external nuclear periphery and the 
cytoplasmic periphery. At the nuclear periphery, the there was a common tendency for the 
clustering of punctate foci. This could be cause by many dynamic behaviors, both cellular and 
protein‐based. It is possible that the export of the fusion protein allows for the concentrate the 
protein in localized region of the nuclear exterior. If all TTV VP3 were exported by a particular 
family of nuclear pore complex, then it may be possible for this trend of clumping and 
clustering to be accentuated in a particular region around the nuclear envelope. TTV VP3’s 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behavior may be controlled by some degree of concentration dependence, such that at only at 
certain concentrations does it aggregate or localize to a particular cellular region 
The aggregated fusion proteins also seemed to appear in the nucleus of the one‐day 
transfected cells. However, many of these nuclear signals are the result of punctuate foci, and 
although they appear in the same region as the nuclear stain, they may in fact be on either 
exterior face of the nuclear envelope. Other cases are clearer, especially when the fusion 
protein is observed to be dispersed fairly uniformly. In these cases, the GFP signal appears to be 
just as strong throughout the cell, indicating that perhaps the fusion protein exists in both the 
cytoplasm and nucleus. Nonetheless, it is possible that the GFP signals are predominantly 
cytoplasmic and only appear to reside in the nucleus.   
The punctate foci, which were so predominantly displayed by many of the one‐day cells, 
seem to play a key behavioral role for VP3 and perhaps provide a clue to the potential biological 
function of the protein. Due to these fusion protein foci, VP3 seems to have a propensity for 
large‐scale aggregation. This would indicate that the functional protein design either allows for 
or causes this self‐aggregation. It would seem likely that the proteins conformation allows for 
this aggregation with minimal processing, as the aggregates distinctly appear in both the 
cytoplasm and nucleus in independent cases.  
The aggregated fusion protein complexes are clearly of highly variable nature, as 
displayed by the many sizes and shapes of the punctate foci. These sizes can vary from highly 
diminutive to obtrusive, almost organelle‐sized aggregates, and their shapes both circular and 
asymmetric. This may indicate that the aggregation is less structured and the potential 
aggregated structure more the result of random interactions and less based on uniformly‐
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repeated linking. This aggregation could be the result of a weak protein‐protein interaction, 
which when compounded by the presence of the protein’s high concentration and close 
proximity, may result in a glomming together of the proteins. In this way, a number of weak 
protein‐protein interactions may have the capacity to build synergistically, ultimately 
aggregating into a stable multi‐protein complex. The proteins may also be interacting 
covalently, and so in their interaction the proteins would be reversibly bonded to one another. 
The protein‐protein linking involved in this sort of aggregation could be the result of a particular 
primary or secondary structure interaction, but this may not be the case due to the almost 
sporadic nature of the fusion protein complexes.  This variety of binding could either be based 
on random interactions or perhaps binding is made more favorable via conformational changes 
within a particular bound protein. 
The presence of the GFP tag on the fusion protein may also act to disturb its in 
vitro behavior, as the protein itself is only 105 residues in length, and so even the small GFP 
fused protein (238 amino acids) dwarfs VP3, and could have any number of spurious effects on 
replicating in vivo protein multimerization.     
In concurrence with Noteborn’s observations of the behavior of TTV‐VP3, at two days 
after transfection the H1299 cells displayed a completely cytoplasmic distribution. [16] 
Obviously, this is a significant transition in overall localization when compared to those 
distributions observed for the one‐day transfections. Unlike the one‐day transfections 
localization—a variable distribution in both the nucleus and cytoplasm, as well as pronounced 
punctate aggregations—the two‐day transfections showed little variance in localization. The 
two‐day transfected cells displayed multimerization, although in markedly different from the 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distribution visualized at the earlier time point. In this case, the aggregates were uniformly 
small and highly dispersed through much of the cytoplasm, giving the fusion protein signals a 
spattered appearance. Near the peripheral interior of the cell membrane the fusion protein 
signals appear lessened, and conversely, the signals appear to be denser proximal to the 
nuclear envelope. The trend towards spattered‐looking distributions of TTV‐VP3 may be due to 
the oversaturation of the cell with these proteins from unconstrained expression of VP3. 
Perhaps this greater level of concentration disturbs the protein’s ability to form larger 
aggregates.  
Simply from its fully cytoplasmic localization two days after transfection, we learned a 
significant fact about TTV VP3. Due to this obvious localization shift from a seemingly 
unlocalized distribution to a purely cytoplasmic one, we have established that TTV VP3 must 
have a functional nuclear export sequence (NES). This is significant as it indicates a notable 
characteristic about TTV VP3’s behavior, which in turn may enable a greater understanding of 
the protein’s intended biological function. Further, it provides us with an inherent future goal: 
to locate the NES and study its effect on TTV VP3 when disrupted. If it is truly similar to apoptin, 
TTV VP3 may also have a nuclear localization sequence and a multimerization sequence—the 
existence and location of which may be revealed by future research. 
The cytoplasmic distribution may be due to a number of factors. If TTV VP3 also has a 
functional nuclear localization sequence (NLS), perhaps the nuclear export of TTV VP3 is 
occurring at a greater rate than its import to the nucleus, and so the state that we observe is 
composed of a skewed equilibrium of export and import. Another possibility is that the fusion 
protein is fully sequestered to the cytoplasm at this point of observation. Perhaps this could be 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caused by a blockage or clog due to the volume of aggregated proteins. Also, the aggregated 
proteins may have become too generally large relative to the passable pores in their relevant 
NPC. The first explanation seems the most likely from our observational data, since there is an 
obvious signal gradient present near the nuclear periphery.  
In addition, there were slightly greater cell concentrations for the control at the forty‐
eight hour time point, when compared to the pVP3‐GFP transfected cells at this same time 
point. Indeed, this may indicate some degree of apoptotic potential, as the lysed cells, loosened 
and degraded, would have been washed away in the fixing stage of slide preparation. This 
observation is speculative and circumstantial, and further, is not fully substantiated by the 
transfection results; however, it merits further exploration into this potential phenomenon. 
Due to similar observed confluence levels (by general observational approximation of 
living cell density) at both one‐day and two‐day transfection time periods, and because at these 
time points we were unable to observe any apoptosis evidence outright, it seems that if 
apoptotic activity exists for TTV VP3 it must be induced at some later time.  
Noteborn et al. observed the VP3 to first take on a finely granular distribution, a 
description which matches our own observations. He observed that this granular stage 
transitioned into large‐scale aggregation which led to the transfected cells becoming apoptotic 
and fragmenting at three to four days. Overall, our two‐day observation is consistent with that 
of Noteborn and colleagues. Further, Noteborn et al. indicated that the localization of TTV VP3 
was cytoplasmic prior to inducing apoptosis; however, he did not further examine or discuss 
the possible mechanism for this apoptosis. To learn whether TTV VP3 truly exerts apoptotic 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activity upon tumorogenic cells, we must conduct a longer period of post‐transfection 
observation before fixing.    
Another powerful clue in revealing potential apoptotic activity of TTV VP3 was 
presented by the simple procedure of crystal violet staining. The noticeable differences in live 
cells between transfected and non‐transfected cell samples is a strong indicator of TTV VP3’s 
activity. One significant component of this result is the consistency of confluency observed 
between both sample wells, which are sparsely populated in contrast to the matted cell growth 
observed in the control well. However, as the differences in confluence levels were first 
observed at four days, further work must be conducted to study TTV VP3’s localization at this 
time point.  
One major difference between our observations for TTV VP3 and those localizations 
observed for apoptin is that our two‐day transfections displayed cytoplasmic localization while 
apoptin displays aggregation in the nucleus prior to inducing apoptosis. Although the observed 
localization for TTV VP3 is different that observed for apoptin, the observed localization of the 
protein coded by PCV ORF3 also induces apoptosis like apoptin, but in the cytoplasm. [4] 
Perhaps the apoptotic activity of TTV VP3 is more similar to that PCV VP3; however, the 
discovery of any further similarity will require a more in depth investigation into potential 
mechanistic similarities. 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Future investigations   
  With the foundation established by this initial research into TTV VP3, any number of 
routes of study lay open to future investigative endeavors. An important follow‐up investigation 
may be first to conduct a more extensive search into—and to conclusively demonstrate—the 
apoptotic activity of TTV VP3. This may be accomplished through a more extensive study into 
the protein’s localization—perhaps using our designed pVP3‐GFP construct, but for more 
extended temporal periods post‐transfection. Further studies using the pVP3‐3xFlag construct 
we designed during our research may reveal present more evidence about TTV VP3’s apoptotic 
ability. 3xFlag’s unobtrusive size may allow for a greater understanding or approximation of TTV 
VP3’s natural behavior when unencumbered by fusion with GFP. By western blotting 3xFlag‐
tagged VP3 using a native gel, it may be also possible to gain some approximation as to the true 
size and number of units composing each aggregated multimer..    
  In addition to learning about TTV VP3’s potential apoptotic activity, there is much that 
can be learned about the role that ORF3’s primary sequence plays in determining the dynamic 
behavior and localization of TTV VP3. By creating sectional constructs, as discussed in the 
previous section, it may be possible to analyze the role of specific sections in controlling TTV 
VP3. If the loss of a particular section eliminates or alters some aspect of its localization or 
behavior, then this may indicate the section’s role in the protein’s function. For instance, if a 
construct is made, minus one or two 20 nt oligonucleotides from the N‐terminal region 
(replaced with a new oligonucleotide with appropriate start codons and restriction sites), and 
the protein is observed to no longer aggregate, then perhaps later studies could be focused 
upon the removed sequence’s role in multimerization. Or similarly, if the protein is seen to exist 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in both the nucleus and cytoplasm two days after transfection then perhaps the truncated 
section could play some role in signaling nuclear export. 
  Future work with TTV VP3 will likely involve altering the function of the protein through 
site‐directed mutagenesis. With greater knowledge regarding the particular functions of TTV 
ORF 3’s primary sequence, future investigators will be able to design primers and change the 
residues produced by specific codons through PCR. In this way, mutated TTV ORF 3 could be 
transfected and observed to study the general effects of the mutation, perhaps disturbing 
localization, activity, or aggregation.  
Investigating the expression and behavior of TTV ORF3 proteins from other genotypes 
may also provide insight into the biological significance of these proteins. Perhaps if similar 
investigations to this one are conducted upon the ORF 3 of other TTV genotypes, researchers 
may gain a greater understanding of the degree of conserved activity for this protein across the 
myriad genotypes of TTV. 
 
Conclusions  
At this stage, much remains to be understood about TTV and the potential of its VP3. 
Years of study have done little to bring us closer to an understanding of TTV’s pathology. In‐
depth studies of TTV’s proteins and its biological behavior have been greatly impeded. Although 
researchers have been working to uncover the properties and behavior of TTV’s proteins, we 
are still left in the dark regarding the role these proteins play in TTV infection and in vivo 
behavior. 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Through our investigations, we have demonstrated that TTV VP3 shows dynamic 
similarities to apoptin from CAV, by forming aggregations in the cytoplasm. Although this 
cytoplasmic localization differs from CAV’s apoptin, it shows similarities to the VP3 of porcine 
circoviruses which form cytoplasmic aggregates and have been shown to selectively trigger 
apoptosis akin to apoptin. [4] Finally, our work demonstrates that TTV VP3 is fully excluded 
from the nucleus at two days after transfection, indicating the presence of a NES in the 
structure of TTV VP3. 
By expressing the protein from TTV ORF 3 in a careful and controlled manner we have 
provided a framework of understanding which future researchers can build upon and grow the 
understanding of TTV VP3. In the process of accomplishing this, we have demonstrated the 
overall effectiveness of PCR‐directed gene synthesis in generating full‐length gene constructs 
from a number of overlapping oligonucleotides. In addition, we have established a genetic 
toolbox of ready‐to‐study genes precloned into a number of expression vectors. Above all, we 
hope that through our work we were able to provide solid grounding for investigations to come 
and that our research and findings were engaging enough to perpetuate and propel future 
studies into TTV VP3. 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Figures 
 
 
Figure 3: General visual overview of PCR‐directed gene synthesis. 
 
 42 
 
 
 
Figure 4: Cladogram representation of TTV group one in association with abbreviated phylogenic distribution, as 
adapted from Hino and Miyata. [9] 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Figure 5: Fluorescence microscopy images of H1299 small‐cell lung carcinoma cells transfected with construct 
pVP3‐GFP. Cells transfected for one day are shown in panels A‐C, while cells transfected for two days are shown in 
panels D,E. The first column displays fusion protein localization signals and the second shows the same image with 
filtered for the nuclear stain DAPI. The Third column shows an overlay of the two images with one image 
transposed upon the other to show both GFP signals and DAPI simultaneously. Control GFP cells shown in * panel. 
 
 44 
 
 
 
 
 
Figure 6: Crystal violet‐stained H1299 cells transfected with pVP3‐Flag construct, fixed at five days after 
transfection. Three wells were used for transfection and crystal violet staining (top), with the left and middle wells 
containing transfected H1299 cells, while the rightmost well contained non‐transfected cells (control). Detail of the 
middle and rightmost wells are shown in the lower panel of the figure.  
 
 
 45 
 
 
 
Works Cited 
1. Abe, K., Inami, T., Asano, K., Miyoshi, C., Masaki, N., Hayashi, S., Ishikawa, I., Takebe, Y., 
Win, K. M., El‐Zayadi A. R., Han K. H., Zhang D. Y., (1999). TT virus infection is widespread in 
the general populations from different geographic regions. J. Clin. Microbiol. 1999, 37:2703‐
2705.  
 
2. Biagini, P., de Micco, P., de Lamballerie, X., (2006). Identification of a third member of the 
Anellovirus genus (‘small anellovirus’) in French blood donors. Arch. Virol. 151, 405–408.  
 
3. Erker, J. C., Leary, T. P., Desai, S. M., Chalmers, M. L. & Mushahwar, I. K. (1999). Analyses of 
TT virus full‐length genomic sequences. J. Gen. Virol. 80, 1743–1750.  
 
4. Finsterbusch, T., Mankertz, A., Porcine circoviruses—Small but powerful. Virus Res. (2009). 
 
5. Hallett, R. L., Clewley, J. P., Bobet, F., McKiernan, P. J. & Teo, C. G. (2000). Characterization 
of a highly divergent TT virus genome. J. Gen. Virol. 81, 2273–2279.  
 
6. Herman, R., Hueurmann, K., Brizzard, B., (2009). 3xFlag: Ultra‐sensitive detection of 
recombinant proteins. Sigma‐Aldrich. 
 
7. Hino S., (2006). TTV, a new human virus with single‐stranded circular DNA genome. Rev 
Med Virol  12: 151–158.  
 
8. Hino, S., Miyata, H., (2007). Torque teno virus (TTV): current status. Reviews in Medical 
Virology 17, 45–57.  
 
9. Hino, S., Prasetyo, A. A. Relationship of Torque Teno Virus to Chicken Anemia Virus. (Book) 
Current Topics in Microbiology and Immunology, TT Viruses: The Still Elusive Human 
Pathogens, (eds.) de Villiers, E.‐M., zur Hausen, H., 2009. 
 
10. ICTVdB. The universal virus database of the International Committee on Taxonomy of 
Viruses. http://www.ictvdb.rothamsted.ac.uk/index.htm.  
 
11. Jelcic, I., Hotz‐Wagenblatt, A., Hunziker, A., zur Hausen, H., and de Villiers, E.‐M., Isolation of 
Multiple TT Virus Genotypes from Spleen Biopsy Tissue from a Hodgkin‘s Disease Patient: 
Genome Reorganization and Diversity in the Hypervariable Region. J. Virol. 73, 1052‐1064. 
 
 46 
 
12. Kamahora, T., Hino, S., Miyata, H., (2000). Three spliced mRNAs of TT virus transcribed from 
a plasmid containing the entire genome in COS1 cells. J. Virol. 74, 9980–9986.  
 
13. Khudyakov, Y. E., Cong, M. E., Nichols, B., Reed, D., Dou, X. G., Viazov, S. O., Chang, J., Fried, 
M. W., Williams, I., (2000). Sequence heterogeneity of TT virus and closely related viruses. J. 
Virol. 74, 2990–3000.  
 
14. Kooistra, K., Zhang, Y. H., Henriquez, N. V., Weiss, B., Mumberg, D., Noteborn, M. H., (2004). 
TT virus‐derived apoptosis‐inducing protein induces apoptosis preferentially in 
hepatocellular carcinoma‐derived cells. J. Gen. Virol., 85: 1445–1450.  
 
15. Leary TP, Erker JC, Chalmers ML, Desai SM, Mushahwar IK. Improved detection systems for 
TT virus reveal high prevalence in humans, non‐human primates and farm animals. J Gen 
Virol 1999; 80: 2115–2120.  
 
16. Miyata, H., Tsunoda, H., Kazi, A., Yamada, A., Khan, M. A., Murakami, J., Kamahora, T., 
Shiraki, K. & Hino, S. (1999). Identification of a novel GC‐rich 113‐nucleotide region to 
complete the circular, single‐stranded DNA genome of TT virus, the first human circovirus. J 
Virol 73, 3582–3586.  
 
17. Naoumov, N. V., E. P. Petrova, M. G. Thomas, and R. Williams. 1998. Presence of a newly 
described human DNA virus (TTV) in patients with liver disease. Lancet 352:195–197.  
 
18. NCI‐Navy Medical Oncology Branch cell line supplement. J. Cell Biochem. Suppl. 1996; 24:1‐
291. 
19. Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA 
virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of 
unknown etiology. Biochem. Biophys. Res. Commun. 1997; 241: 92–97.  
 
20. Noteborn MH. Chicken anemia virus induced apoptosis: underlying molecular mechanisms. 
Vet. Microbiol. 2004; 98: 89–94.  
 
21. Okamoto H, Fukuda M, Tawara A, et al. Species specific TT viruses and cross‐species 
infection in nonhuman primates. J. Virol. 2000; 74: 1132–1139.  
 
22. Okamoto, H., Takahashi, M., Nishizawa, T., Tawara, A., Fukai, K., Muramatsu, U., Naito, Y. & 
Yoshikawa, A. (2002). Genomic characterization of TT viruses (TTVs) in pigs, cats and dogs 
and their relatedness with species‐specific TTVs in primates and tupaias. J. Gen. Virol. 83, 
1291–1297.  
 
23. Okamoto, H., Nishizawa, T. & Takahashi, M. (2004). Torque teno virus (TTV): molecular 
virology and clinical implications. In Viral Hepatitis: Molecular Biology, Diagnosis, 
Epidemiology and Control, pp. 241–254. Edited by I. K. Mushahwar. California: Elsevier.  
 47 
 
 
24. Pollicino T, Raffa G, Squadrito G, Costantino L, Cacciola I, Brancatelli S, Alafaci C, Florio MG, 
Raimondo G: TT virus has ubiquitous diffusion in human body tissues: analyses of paired 
serum and tissue samples. J Viral Hepat 2003, 10:95‐102.  
 
25. Qiu, J., Kakkola, L., Cheng, F., Ye, C., Soderlund‐Venermo, M., Hedman, K., Pintel, D.J., 2005. 
Human circovirus TT virus genotype 6 expresses six proteins following transfection of a full‐
length clone. Journal of Virology 79, 6505–6510.  
 
26. Simmonds P, Prescott LE, Logue C, Davidson F, Thomas AE, Ludlam CA: TT virus—part of the 
normal human flora? J. Infect. Dis. 1999, 180:1748‐1750. 
 
27. de Smit M. H., Noteborn, M. H. M., Apoptosis‐Inducing Proteins in Chicken Anemia Virus 
and TT Virus. (Book) Current Topics in Microbiology and Immunology, TT Viruses: The Still 
Elusive Human Pathogens, (eds.) de Villiers, E.‐M., zur Hausen, H., 2009.  
 
28. Stremmer, Willem P. C., Crameri,  Andreas, Kim D. Ha, Thomas M. Brennan and Herbert L. 
Heyneker. Single‐step assembly of a gene and entire plasmid from large numbers of 
oligodeoxyribonucleotides. Gene, 1995; 164:49‐53. 
 
29. Takahashi, K., Iwasa, Y., Hijikata, M., Mishiro, S., (2000). Identification of a new human DNA 
virus (TTV‐like mini virus, TLMV) intermediately related to TT virus and chicken anemia 
virus. Arch. Virol. 145: 979–993. 
 
30. Zhong S, Yeo W, Tang MW, Lin XR, Mo F, Ho WM, Hui P, Johnson PJ. 
2001. Gross elevation of TT virus genome load in the peripheral 
blood mononuclear cells of cancer patients. Ann. N Y Acad. Sci. 945‐56. 
 
